MAY 23, 2016 8:00 AM PDT

Heparin monitoring - Here to stay!

Sponsored by: Diagnostica Stago, Inc.
  • Professor, Department of Pharmacy Practice, Campbell University School of Pharmacy, Clinical Assistant Professor of Medicine, University of North Carolina School of Medicine, Clinical Pharm
      James B Groce Ill, PharmD, CACP, is Professor, Department of Pharmacy Practice at Campbell University School of Pharmacy. Dr. Groce also is Clinical Assistant Professor of Medicine at the University of North Carolina School of Medicine and Clinical Pharmacy Specialist-Anticoagulation at the Moses H. Cone Memorial Hospital in Greensboro, North Carolina, where he manages an anticoagulation clinic serving over 100 patients and supervises pharmacy practice and medicine residents training in anticoagulation management at this site. He served as principal investigator at Moses H. Cone Health System for DVT FREE, a national registry trial examining risk factors and prevalence of DW. Additionally, he was part of the II- member steering committee for this initiative. He represents pharmacy nationally on the Council for Leadership on Thrombosis Awareness and Management (CLOT Council) as its sole pharmacist member on this physician-based panel of National thought leaders and experts on thromboembolism as well as the Coalition Against DW in the same capacity. He was recently appointed to the Technical Advisory Panel of JCAHOINQF for creation of core measures for prevention and treatment of venous thromboembolism. Most recently, he was named Preceptor of the Year by the graduating classes of 2006 and 2007, Campbell University School of Pharmacy. Dr. Groce has been published and cited in peer-reviewed medical and pharmacy journals as well as textbooks of pharmacy. He has presented extensively regarding the interchange of Narrow Therapeutic Index Drugs and its impact with respect to efficacy and safety, and pharmacoeconmics; he gave testimony before the state Senate and House Subcommittees of the North Carolina Legislature examining this issue that resulted in Senate Bill 945 - The Prescription Refill Safety Act. He is certified by the National Certification Board of Anticoagulation Providers and currently is a sitting member of its Board of Directors.


    We celebrate the centennial of the discovery of heparin this year. Even after 100 years, heparin is still one of the most prescribed anticoagulants.  The clinical laboratory plays a central role in the management of patients receiving heparin.  During this webinar, the differences between unfractionated heparin (UFH) and low-molecular-weight-heparin (LMWH) will be described as well as the impact these differences may have relative to monitoring. The traditional surrogate marker(s) used as a means of monitoring and measuring efficacy and safety of UFH and LMWH will be detailed and advantages and disadvantages will be identified with a focus upon reference range and limitations of the aPTT, and the benefit of anti-Xa monitoring of UFH and LMWH. Management strategies for appropriate use of anti-Xa heparin level determinations will be discussed.

    • Describe the differences between unfractionated and low molecular weight heparins along with the impact of the formulation differences on monitoring tests.
    • Describe details and limitations of monitoring tests to measure safety and efficacy of unfractionated and low molecular weight heparins.
    • Discuss advantages of the use of the anti-Xa assay to monitor unfractionated and low molecular weight heparins.

    Show Resources
    Show Resources
    • See more